{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:52:27Z","timestamp":1792871547786,"version":"4.5.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00228-025-03830-w","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T23:17:50Z","timestamp":1743722270000},"page":"801-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of oral antidiabetic agents on the renin\u2013angiotensin\u2013aldosterone system"],"prefix":"10.1007","volume":"81","author":[{"given":"Xifeng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxuan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"issue":"3","key":"3830_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.trsl.2008.12.008","volume":"153","author":"R Nistala","year":"2009","unstructured":"Nistala R, Wei Y, Sowers JR, Whaley-Connell A (2009) Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. Transl Res 153(3):102\u2013113","journal-title":"Transl Res"},{"issue":"2","key":"3830_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jvim.15454","volume":"33","author":"Ames Ma-O","year":"2019","unstructured":"Ma-O Ames, Atkins CE, Pitt B (2019) The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med 33(2):363\u2013382","journal-title":"J Vet Intern Med"},{"key":"3830_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41440-017-0008-y","volume":"41","author":"D Yamazaki","year":"2018","unstructured":"Yamazaki D, Hitomi H, Nishiyama A (2018) Hypertension with diabetes mellitus complications. Hypertens Res 41:147\u2013156","journal-title":"Hypertens Res"},{"key":"3830_CR4","doi-asserted-by":"crossref","unstructured":"Demarsilis A et al (2022) Pharmacotherapy of type 2 diabetes: an update and future directions. Metabolism 137","DOI":"10.1016\/j.metabol.2022.155332"},{"key":"3830_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s11906-012-0245-z","volume":"14","author":"T Thethi","year":"2012","unstructured":"Thethi T, Kamiyama M, Kobori H (2012) The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 14:160\u2013169","journal-title":"Curr Hypertens Rep"},{"key":"3830_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1124\/pr.59.3.3","volume":"59","author":"H Kobori","year":"2007","unstructured":"Kobori H, Nangaku M, Navar LG, Nishiyama A (2007) The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59:251\u2013287","journal-title":"Pharmacol Rev"},{"key":"3830_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrneph.2010.30","volume":"6","author":"M Briet","year":"2010","unstructured":"Briet M, Schiffrin EL (2010) Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 6:261\u2013273","journal-title":"Nat Rev Nephrol"},{"key":"3830_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s12576-019-00679-4","volume":"69","author":"E Takimoto-Ohnishi","year":"2019","unstructured":"Takimoto-Ohnishi E, Murakami K (2019) Renin-angiotensin system research: from molecules to the whole body. J Physiol Sci 69:581\u2013587","journal-title":"J Physiol Sci"},{"key":"3830_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2012.06.021","volume":"378","author":"Y Marcus","year":"2013","unstructured":"Marcus Y, Shefer G, Stern N (2013) Adipose tissue renin-angiotensin-aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol 378:1\u201314","journal-title":"Mol Cell Endocrinol"},{"key":"3830_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1113\/expphysiol.2011.060673","volume":"97","author":"Y Qi","year":"2012","unstructured":"Qi Y et al (2012) Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury. Exp Physiol 97:89\u2013101","journal-title":"Exp Physiol"},{"issue":"1","key":"3830_CR11","first-page":"05","volume":"98","author":"Santos Ra-O","year":"2018","unstructured":"Ra-O Santos et al (2018) The ACE2\/angiotensin-(1\u20137)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1\u20137). Physiol Rev 98(1):05\u2013553","journal-title":"Physiol Rev"},{"issue":"2","key":"3830_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/hr.2010.235","volume":"34","author":"LA Rabelo","year":"2011","unstructured":"Rabelo LA, Alenina N, Bader M (2011) ACE2-angiotensin-(1\u20137)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res 34(2):154\u2013160","journal-title":"Hypertens Res"},{"key":"3830_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000313363","volume":"31","author":"HM Siragy","year":"2010","unstructured":"Siragy HM, Carey RM (2010) Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 31:541\u2013550","journal-title":"Am J Nephrol"},{"key":"3830_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF00583388","volume":"281","author":"IA Darby","year":"1995","unstructured":"Darby IA, Sernia C (1995) In situ hybridization and immunohistochemistry of renal angiotensinogen in neonatal and adult rat kidneys. Cell Tissue Res 281:197\u2013206","journal-title":"Cell Tissue Res"},{"key":"3830_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1172\/JCI114454","volume":"85","author":"JR Ingelfinger","year":"1990","unstructured":"Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ (1990) In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest 85:417\u2013423","journal-title":"J Clin Invest"},{"key":"3830_CR16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1161\/01.HYP.0000122875.91100.28","volume":"43","author":"H Kobori","year":"2004","unstructured":"Kobori H, Prieto-Carrasquero MC, Ozawa Y, Navar LG (2004) AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension 43:1126\u20131132","journal-title":"Hypertension"},{"key":"3830_CR17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3389\/fendo.2021.738848","volume":"12","author":"S Puglisi","year":"2021","unstructured":"Puglisi S et al (2021) Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front Endocrinol 12:738\u2013848","journal-title":"Front Endocrinol"},{"key":"3830_CR18","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1152\/ajplegacy.1973.224.4.926","volume":"224","author":"RE Shade","year":"1973","unstructured":"Shade RE, Davis JO, Johnson JA, Gotshall RW, Spielman WS (1973) Mechanism of action of antiotensin II and antidiuretic hormone on renin secretion. Am J Physiol-Leg Content 224:926\u2013929","journal-title":"Am J Physiol-Leg Content"},{"key":"3830_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S0895-7061(01)02284-1","volume":"15","author":"G Prescott","year":"2002","unstructured":"Prescott G, Silversides DW, Reudelhuber TL (2002) Tissue activity of circulating prorenin. Am J Hypertens 15:280\u2013285","journal-title":"Am J Hypertens"},{"issue":"7","key":"3830_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/01.RES.85.7.643","volume":"85","author":"DE Dostal","year":"1999","unstructured":"Dostal DE, Baker KM (1999) The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 85(7):643\u2013650","journal-title":"Circ Res"},{"issue":"3","key":"3830_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/ijms20030629","volume":"20","author":"TM Ansary","year":"2019","unstructured":"Ansary TM, Nakano D, Nishiyama A (2019) Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci 20(3):629","journal-title":"Int J Mol Sci"},{"key":"3830_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587\u2013597","journal-title":"Circulation"},{"key":"3830_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11255-020-02585-w","volume":"53","author":"AM Castaneda","year":"2021","unstructured":"Castaneda AM et al (2021) Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications. Int Urol Nephrol 53:291\u2013299","journal-title":"Int Urol Nephrol"},{"key":"3830_CR24","doi-asserted-by":"publisher","first-page":"8917578","DOI":"10.1155\/2016\/8917578","volume":"2016","author":"S Bernardi","year":"2016","unstructured":"Bernardi S, Michelli A, Zuolo G, Candido R, Fabris B (2016) Update on RAAS modulation for the treatment of diabetic cardiovascular dIsease. J Diabetes Res 2016:8917578","journal-title":"J Diabetes Res"},{"key":"3830_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jvim.15454","volume":"33","author":"MK Ames","year":"2019","unstructured":"Ames MK, Atkins CE, Pitt B (2019) The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med 33:363\u2013382","journal-title":"J Vet Intern Med"},{"issue":"2","key":"3830_CR26","doi-asserted-by":"publisher","first-page":"R428","DOI":"10.1152\/ajpregu.90753.2008","volume":"96","author":"P Bie","year":"2009","unstructured":"Bie P, M\u00f8lstr\u00f8m S, Wamberg S (2009) Normotensive sodium loading in conscious dogs: regulation of renin secretion during beta-receptor blockade. Am J Physiol Regul Integr Comp Physiol 96(2):R428-435","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3830_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","volume":"14","author":"RA Defronzo","year":"2012","unstructured":"Defronzo RA, Davidson JA, Del Prato S (2012) The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 14:5\u201314","journal-title":"Diabetes Obes Metab"},{"key":"3830_CR28","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.2337\/dc22-0921","volume":"45","author":"AO Gerard","year":"2022","unstructured":"Gerard AO, Laurain A, Favre G, Drici MD, Esnault VLM (2022) Activation of the tubulo-glomerular feedback by SGLT2 inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: toward the end of a myth? Diabetes Care 45:e148\u2013e149","journal-title":"Diabetes Care"},{"key":"3830_CR29","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.numecd.2020.05.030","volume":"30","author":"R Sarzani","year":"2020","unstructured":"Sarzani R, Giulietti F, Di Pentima C, Spannella F (2020) Sodium-glucose co-transporter-2 inhibitors: peculiar \u201chybrid\u201d diuretics that protect from target organ damage and cardiovascular events. Nutr Metab Cardiovasc Dis 30:1622\u20131632","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"3830_CR30","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","volume":"83","author":"A Marton","year":"2024","unstructured":"Marton A et al (2024) Water conservation overrides osmotic diuresis during SGLT2 Inhibition in patients with heart failure. J Am Coll Cardiol 83(5):1386\u20131398","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"3830_CR31","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.numecd.2020.05.030","volume":"30","author":"R Sarzani","year":"2020","unstructured":"Sarzani R, Giulietti F, Di Pentima C, Spannella F (2020) Sodium-glucose co-transporter-2 inhibitors: peculiar \u201chybrid\u201d diuretics that protect from target organ damage and cardiovascular events. Nutr Metab Cardiovasc Dis 30(10):1622\u20131632","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"11","key":"3830_CR32","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMc1600140","volume":"374","author":"B Zinman","year":"2016","unstructured":"Zinman B, Lachin JM, Inzucchi SE (2016) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 374(11):1094","journal-title":"N Engl J Med"},{"key":"3830_CR33","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/1440-1681.12725","volume":"44","author":"A Rahman","year":"2017","unstructured":"Rahman A, Fujisawa Y, Nakano D, Hitomi H, Nishiyama A (2017) Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats. Clin Exp Pharmacol Physiol 44:522\u2013525","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"3830_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/fendo.2018.00421","volume":"9","author":"N Wan","year":"2018","unstructured":"Wan N, Rahman A, Hitomi H, Nishiyama A (2018) The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity. Front Endocrinol (Lausanne) 9:421","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3830_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s13300-011-0002-3","volume":"2","author":"C Koliaki","year":"2011","unstructured":"Koliaki C, Doupis J (2011) Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther 2:101\u2013121","journal-title":"Diabetes Ther"},{"key":"3830_CR36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728\u2013742","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"3830_CR37","doi-asserted-by":"publisher","first-page":"R983","DOI":"10.1152\/ajpregu.00323.2007","volume":"293","author":"KA Scott","year":"2007","unstructured":"Scott KA, Moran TH (2007) The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 293(3):R983-987","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3830_CR38","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131\u20132157","journal-title":"Gastroenterology"},{"issue":"2","key":"3830_CR39","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/jpet.110.176362","volume":"336","author":"D Wootten","year":"2011","unstructured":"Wootten D et al (2011) Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids. J Pharmacol Exp Ther 336(2):540\u2013550","journal-title":"J Pharmacol Exp Ther"},{"key":"3830_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11154-014-9287-7","volume":"15","author":"J Skov","year":"2014","unstructured":"Skov J (2014) Effects of GLP-1 in the kidney. Rev Endocr Metab Disord 15:197\u2013207","journal-title":"Rev Endocr Metab Disord"},{"issue":"0","key":"3830_CR41","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.3390\/ijms20081940","volume":"20","author":"JI Beraldo","year":"2019","unstructured":"Beraldo JI et al (2019) Cardioprotection conferred by sitagliptin is associated with reduced cardiac angiotensin II\/angiotensin-(1\u20137) balance in experimental chronic kidney disease. Int J Mol Sci 20(0):1940","journal-title":"Int J Mol Sci"},{"key":"3830_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/HCO.0b013e3281532b53","volume":"22","author":"H Hitomi","year":"2007","unstructured":"Hitomi H, Kiyomoto H, Nishiyama A (2007) Angiotensin II and oxidative stress. Curr Opin Cardiol 22:311\u2013315","journal-title":"Curr Opin Cardiol"},{"key":"3830_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/08037050310001057","volume":"12","author":"E Kaschina","year":"2003","unstructured":"Kaschina E, Unger T (2003) Angiotensin AT1\/AT2 receptors: regulation, signalling and function. Blood Press 12:70\u201388","journal-title":"Blood Press"},{"key":"3830_CR44","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ki.2013.427","volume":"85","author":"H Fujita","year":"2014","unstructured":"Fujita H et al (2014) The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 85:579\u2013589","journal-title":"Kidney Int"},{"issue":"11","key":"3830_CR45","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.2337\/db11-1824","volume":"61","author":"A Mima","year":"2012","unstructured":"Mima A et al (2012) Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKC\u03b2 activation in diabetes. Diabetes 61(11):2967\u20132979","journal-title":"Diabetes"},{"key":"3830_CR46","doi-asserted-by":"publisher","first-page":"E641","DOI":"10.1152\/ajpendo.00429.2014","volume":"308","author":"A Asmar","year":"2015","unstructured":"Asmar A et al (2015) Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am J Physiol Endocrinol Metab 308:E641-649","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3830_CR47","doi-asserted-by":"publisher","first-page":"117916","DOI":"10.1016\/j.lfs.2020.117916","volume":"256","author":"H Yaribeygi","year":"2020","unstructured":"Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A (2020) Incretin-based therapies and renin-angiotensin system: looking for new therapeutic potentials in the diabetic milieu. Life Sci 256:117916","journal-title":"Life Sci"},{"issue":"2","key":"3830_CR48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/dom.12804","volume":"19","author":"MS Abd El Aziz","year":"2017","unstructured":"Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA (2017) A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 19(2):216\u2013227","journal-title":"Diabetes Obes Metab"},{"key":"3830_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.yjmcc.2016.06.066","volume":"98","author":"H Kawase","year":"2016","unstructured":"Kawase H et al (2016) A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II\/sodium-proton pump exchanger-1 axis. J Mol Cell Cardiol 98:37\u201347","journal-title":"J Mol Cell Cardiol"},{"key":"3830_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10557-015-6592-7","volume":"29","author":"LH Zhang","year":"2015","unstructured":"Zhang LH et al (2015) Preservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT1\/AT 2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart. Cardiovasc Drugs Ther 29:243\u2013255","journal-title":"Cardiovasc Drugs Ther"},{"key":"3830_CR51","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.2147\/DDDT.S213910","volume":"13","author":"RH Zheng","year":"2019","unstructured":"Zheng RH et al (2019) Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats. Drug Des Devel Ther 13:2745\u20132757","journal-title":"Drug Des Devel Ther"},{"key":"3830_CR52","doi-asserted-by":"publisher","first-page":"172844","DOI":"10.1016\/j.ejphar.2019.172844","volume":"867","author":"F Bai","year":"2020","unstructured":"Bai F et al (2020) Conservation of glucagon like peptide-1 level with liraglutide and linagilptin protects the kidney against angiotensin II-induced tissue fibrosis in rats. Eur J Pharmacol 867:172844","journal-title":"Eur J Pharmacol"},{"key":"3830_CR53","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41440-018-0085-6","volume":"41","author":"K Tamura","year":"2018","unstructured":"Tamura K, Yamaji T, Yamada T, Ohsawa M, Wakui H (2018) An interesting cross-talk between the glucagon-like peptide-1 receptor axis and angiotensin receptor pathway for modulation of renal sodium handling in obesity. Hypertens Res 41:784\u2013786","journal-title":"Hypertens Res"},{"key":"3830_CR54","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/apha.12236","volume":"210","author":"KP Yip","year":"2014","unstructured":"Yip KP, Tse CM (2014) Modulation of Na(+)\/H(+) exchanger 3 trafficking and activity in rat proximal tubule. Acta Physiol (Oxf) 210:458\u2013459","journal-title":"Acta Physiol (Oxf)"},{"issue":"3","key":"3830_CR55","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1046\/j.1523-1755.2003.00189.x","volume":"64","author":"D Du Cheyron","year":"2003","unstructured":"Du Cheyron D et al (2003) Angiotensin II stimulates NHE3 activity by exocytic insertion of the transporter: role of PI 3-kinase. Kidney Int 64(3):939\u2013949","journal-title":"Kidney Int"},{"key":"3830_CR56","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1046\/j.1523-1755.2003.00189.x","volume":"64","author":"D Du Cheyron","year":"2003","unstructured":"Du Cheyron D et al (2003) Angiotensin II stimulates NHE3 activity by exocytic insertion of the transporter: role of PI 3-kinase. Kidney Int 64:939\u2013949","journal-title":"Kidney Int"},{"key":"3830_CR57","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nm.3128","volume":"19","author":"M Kim","year":"2013","unstructured":"Kim M et al (2013) GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19:567\u2013575","journal-title":"Nat Med"},{"key":"3830_CR58","doi-asserted-by":"publisher","first-page":"F1647","DOI":"10.1152\/ajprenal.00082.2009","volume":"297","author":"LR Carraro-Lacroix","year":"2009","unstructured":"Carraro-Lacroix LR, Malnic G, Girardi AC (2009) Regulation of Na+\/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 297:F1647-1655","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"3830_CR59","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/MOL.0b013e3283321d37","volume":"20","author":"H Yki-J\u00e4rvinen","year":"2009","unstructured":"Yki-J\u00e4rvinen H (2009) Thiazolidinediones and the liver in humans. Curr Opin Lipidol 20(6):477\u2013483","journal-title":"Curr Opin Lipidol"},{"issue":"9","key":"3830_CR60","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1097\/00004872-200409000-00022","volume":"22","author":"PA Sarafidis","year":"2004","unstructured":"Sarafidis PA et al (2004) Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 22(9):1769\u20131777","journal-title":"J Hypertens"},{"issue":"9493","key":"3830_CR61","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279\u20131289","journal-title":"Lancet"},{"issue":"4","key":"3830_CR62","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11906-009-0041-6","volume":"11","author":"M Hamblin","year":"2009","unstructured":"Hamblin M, Chang L, Zhang J, Chen YE (2009) The role of peroxisome proliferator-activated receptor gamma in blood pressure regulation. Curr Hypertens Rep 11(4):239\u2013245","journal-title":"Curr Hypertens Rep"},{"issue":"4","key":"3830_CR63","first-page":"215","volume":"47","author":"R Komers","year":"1998","unstructured":"Komers R, Vr\u00e1na A (1998) Thiazolidinediones\u2013tools for the research of metabolic syndrome X. Physiol Res 47(4):215\u2013225","journal-title":"Physiol Res"},{"issue":"5","key":"3830_CR64","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4158\/EP.9.5.406","volume":"9","author":"S Mudaliar","year":"2003","unstructured":"Mudaliar S, Chang AR, Henry RR (2003) Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 9(5):406\u2013416","journal-title":"Endocr Pract"},{"issue":"7","key":"3830_CR65","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1592\/phco.23.7.945.32721","volume":"23","author":"RL Page 2nd","year":"2003","unstructured":"Page RL 2nd, Gozansky WS, Ruscin JM (2003) Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy 23(7):945\u2013954","journal-title":"Pharmacotherapy"},{"issue":"4","key":"3830_CR66","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/ajhp\/61.4.390","volume":"61","author":"KA King","year":"2004","unstructured":"King KA, Levi VE (2004) Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione. Am J Health Syst Pharm 61(4):390\u2013393","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"3830_CR67","doi-asserted-by":"publisher","first-page":"e013927","DOI":"10.1136\/bmjopen-2016-013927","volume":"7","author":"HW Liao","year":"2017","unstructured":"Liao HW et al (2017) Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 7(1):e013927","journal-title":"BMJ Open"},{"issue":"4","key":"3830_CR68","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1021\/jm990554g","volume":"43","author":"TM Willson","year":"2000","unstructured":"Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43(4):527\u2013550","journal-title":"J Med Chem"},{"issue":"8","key":"3830_CR69","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.bbalip.2007.03.006","volume":"177","author":"S Heikkinen","year":"2007","unstructured":"Heikkinen S, Auwerx J, Argmann CA (2007) PPARgamma in human and mouse physiology. Biochim Biophys Acta 177(8):999\u20131013","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"3830_CR70","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1161\/01.HYP.0000116303.71408.c2","volume":"43","author":"MJ Ryan","year":"2004","unstructured":"Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD (2004) PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43(3):661\u2013666","journal-title":"Hypertension"},{"issue":"3","key":"3830_CR71","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3317\/jraas.2006.028","volume":"7","author":"MC Lansang","year":"2006","unstructured":"Lansang MC, Coletti C, Ahmed S, Gordon MS, Hollenberg NK (2006) Effects of the PPAR-gamma agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes. J Renin Angiotensin Aldosterone Syst 7(3):175\u2013180","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"5","key":"3830_CR72","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1161\/HYPERTENSIONAHA.107.092817","volume":"50","author":"VT Todorov","year":"2007","unstructured":"Todorov VT, Desch M, Schmitt-Nilson N, Todorova A, Kurtz A (2007) Peroxisome proliferator-activated receptor-gamma is involved in the control of renin gene expression. Hypertension 50(5):939\u2013944","journal-title":"Hypertension"},{"issue":"1","key":"3830_CR73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3904\/kjim.2011.26.1.19","volume":"26","author":"A Sugawara","year":"2011","unstructured":"Sugawara A et al (2011) PPAR\u03b3 agonist beyond glucose lowering effect. Korean J Intern Med 26(1):19\u201324","journal-title":"Korean J Intern Med"},{"issue":"19","key":"3830_CR74","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1161\/01.CIR.0000016049.86468.23","volume":"105","author":"QN Diep","year":"2002","unstructured":"Diep QN et al (2002) Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105(19):2296\u20132302","journal-title":"Circulation"},{"issue":"1","key":"3830_CR75","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1161\/01.HYP.0000196728.05488.c3","volume":"47","author":"K Benkirane","year":"2006","unstructured":"Benkirane K, Viel EC, Amiri F, Schiffrin EL (2006) Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 47(1):102\u2013108","journal-title":"Hypertension"},{"key":"3830_CR76","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1475-2840-10-10","volume":"10","author":"L Ren","year":"2011","unstructured":"Ren L et al (2011) Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro. Cardiovasc Diabetol 10:10","journal-title":"Cardiovasc Diabetol"},{"key":"3830_CR77","first-page":"603409","volume":"2014","author":"W Zhang","year":"2014","unstructured":"Zhang W et al (2014) Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. ScientificWorldJournal 2014:603409","journal-title":"ScientificWorldJournal"},{"issue":"9","key":"3830_CR78","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/labinvest.2009.45","volume":"89","author":"Y Ji","year":"2009","unstructured":"Ji Y, Liu J, Wang Z, Liu N, Gou W (2009) PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest 89(9):887\u2013902","journal-title":"Lab Invest"},{"issue":"1","key":"3830_CR79","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1677\/JME-10-0088","volume":"46","author":"A Uruno","year":"2011","unstructured":"Uruno A et al (2011) Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production. J Mol Endocrinol 46(1):37\u201349","journal-title":"J Mol Endocrinol"},{"key":"3830_CR80","first-page":"237856","volume":"2009","author":"ER Blasi","year":"2009","unstructured":"Blasi ER et al (2009) Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy Sprague-Dawley rats. Res 2009:237856","journal-title":"Res"},{"issue":"26","key":"3830_CR81","doi-asserted-by":"publisher","first-page":"9406","DOI":"10.1073\/pnas.0501744102","volume":"102","author":"H Zhang","year":"2005","unstructured":"Zhang H et al (2005) Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A 102(26):9406\u20139411","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"3830_CR82","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/FPC.0b013e32830a6ea0","volume":"18","author":"WJ Geese","year":"2008","unstructured":"Geese WJ et al (2008) Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists. Pharmacogenet Genomics 18(10):903\u2013910","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"3830_CR83","first-page":"1007","volume":"35","author":"GR Dagenais","year":"2008","unstructured":"Dagenais GR, Gerstein HC et al (2008) Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 35(1):1007\u20131014","journal-title":"Diabetes Care"},{"issue":"5","key":"3830_CR84","doi-asserted-by":"publisher","first-page":"907","DOI":"10.5114\/aoms.2012.31622","volume":"8","author":"AF Cicero","year":"2012","unstructured":"Cicero AF, Tartagni E, Ertek S (2012) Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci 8(5):907\u2013917","journal-title":"Arch Med Sci"},{"issue":"5754","key":"3830_CR85","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1126\/science.1120781","volume":"310","author":"RJ Shaw","year":"2005","unstructured":"Shaw RJ et al (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310(5754):1642\u20131646","journal-title":"Science"},{"issue":"5","key":"3830_CR86","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1445-5994.1991.tb01375.x","volume":"21","author":"HD Mcintyre","year":"1991","unstructured":"Mcintyre HD et al (1991) Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Aust N Z J Med 21(5):714\u2013719","journal-title":"Aust N Z J Med"},{"issue":"2","key":"3830_CR87","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0005-2736(01)00352-2","volume":"1513","author":"TA Lutz","year":"2001","unstructured":"Lutz TA, Estermann A, Haag A, Scharrer E (2001) Depolarization of the liver cell membrane by metformin. Biochim Biophys Acta 1513(2):176\u2013184","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"3830_CR88","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00125-010-1937-z","volume":"54","author":"A Maida","year":"2011","unstructured":"Maida A, Lamont BJ, Cao X, Drucker DJ (2011) Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-\u03b1 in mice. Diabetologia 54(2):339\u2013349","journal-title":"Diabetologia"},{"issue":"1","key":"3830_CR89","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bbrc.2004.09.021","volume":"324","author":"JM Lenhard","year":"2004","unstructured":"Lenhard JM, Croom DK, Minnick DT (2004) Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 324(1):92\u201397","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"3830_CR90","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1053\/meta.2001.24192","volume":"50","author":"CJ Glueck","year":"2001","unstructured":"Glueck CJ et al (2001) Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 50(7):856\u2013861","journal-title":"Metabolism"},{"issue":"2","key":"3830_CR91","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.amjmed.2007.09.016","volume":"121","author":"SR Salpeter","year":"2008","unstructured":"Salpeter SR, Buckley NS, Kahn JA, Salpeter EE (2008) Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 121(2):149\u2013157","journal-title":"Am J Med"},{"issue":"1","key":"3830_CR92","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1046\/j.1463-1326.2002.00181.x","volume":"4","author":"A Gokcel","year":"2002","unstructured":"Gokcel A et al (2002) Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 4(1):49\u201355","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"3830_CR93","doi-asserted-by":"publisher","first-page":"e43056","DOI":"10.1371\/journal.pone.0043056","volume":"7","author":"Y Kita","year":"2012","unstructured":"Kita Y et al (2012) Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One 7(9):e43056","journal-title":"PLoS One"},{"issue":"12","key":"3830_CR94","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.4049\/jimmunol.0803563","volume":"182","author":"N Nath","year":"2009","unstructured":"Nath N et al (2009) Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol 182(12):8005\u20138014","journal-title":"J Immunol"},{"issue":"4","key":"3830_CR95","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3322\/caac.20078","volume":"60","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E et al (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60(4):207\u2013221","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"3830_CR96","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrneph.2017.105","volume":"13","author":"CM Rhee","year":"2017","unstructured":"Rhee CM, Kalantar-Zadeh K (2017) Diabetes mellitus: complex interplay between metformin, AKI and lactic acidosis. Nat Rev Nephrol 13(9):521\u2013522","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"3830_CR97","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"G Zhou","year":"2001","unstructured":"Zhou G et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108(8):1167\u20131174","journal-title":"J Clin Invest"},{"key":"3830_CR98","doi-asserted-by":"crossref","unstructured":"Liu J et al (2019) AMPK: a balancer of the renin-angiotensin system. Biosci Rep 39(9):BSR20181994","DOI":"10.1042\/BSR20181994"},{"key":"3830_CR99","doi-asserted-by":"publisher","first-page":"101425","DOI":"10.1016\/j.isci.2020.101425","volume":"23","author":"A Malhotra","year":"2020","unstructured":"Malhotra A, Hepokoski M, Mccowen KC, S JYJ (2020) ACE2, Metformin, and COVID-19. iScience 23:101425","journal-title":"iScience"},{"issue":"4","key":"3830_CR100","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1164\/rccm.201712-2570OC","volume":"198","author":"J Zhang","year":"2018","unstructured":"Zhang J et al (2018) AMP-activated protein kinase phosphorylation of angiotensin-converting enzyme 2 in endothelium mitigates pulmonary hypertension. Am J Respir Crit Care Med 198(4):509\u2013520","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3830_CR101","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/01.AOG.0000167408.30893.6b","volume":"106","author":"A Dokras","year":"2005","unstructured":"Dokras A et al (2005) Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 106(1):131\u2013137","journal-title":"Obstet Gynecol"},{"issue":"4771","key":"3830_CR102","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1126\/science.3529392","volume":"233","author":"N Glorioso","year":"1986","unstructured":"Glorioso N, Atlas SA, Laragh JH, Jewelewicz R, Sealey JE (1986) Prorenin in high concentrations in human ovarian follicular fluid. Science 233(4771):1422\u20131424","journal-title":"Science"},{"issue":"2","key":"3830_CR103","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S0015-0282(16)56098-1","volume":"60","author":"A Palumbo","year":"1993","unstructured":"Palumbo A et al (1993) Immunohistochemical localization of renin and angiotensin in the ovary: comparison between normal women and patients with histologically proven polycystic ovarian disease. Fertil Steril 60(2):280\u2013284","journal-title":"Fertil Steril"},{"issue":"4","key":"3830_CR104","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1210\/edrv-1-4-365","volume":"1","author":"JE Sealey","year":"1980","unstructured":"Sealey JE, Atlas SA, Laragh JH (1980) Prorenin and other large molecular weight forms of renin. Endocr Rev 1(4):365\u2013391","journal-title":"Endocr Rev"},{"issue":"1","key":"3830_CR105","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000201791","volume":"32","author":"E Diamanti-Kandarakis","year":"2009","unstructured":"Diamanti-Kandarakis E et al (2009) Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. Kidney Blood Press Res 32(1):24\u201331","journal-title":"Kidney Blood Press Res"},{"issue":"21","key":"3830_CR106","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.2174\/138161208785294609","volume":"14","author":"DA Motta","year":"2008","unstructured":"Motta DA (2008) Metformin in the treatment of polycystic ovary syndrome. Curr Pharm Des 14(21):2121\u20132125","journal-title":"Curr Pharm Des"},{"issue":"6","key":"3830_CR107","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3109\/00365519109104558","volume":"51","author":"H Takahashi","year":"1991","unstructured":"Takahashi H et al (1991) Hyperglycaemia but not hyperinsulinaemia prevents the secretion of glucagon-like peptide-1 (7\u201336 amide) stimulated by fat ingestion. Scand J Clin Lab Invest 51(6):499\u2013507","journal-title":"Scand J Clin Lab Invest"},{"key":"3830_CR108","doi-asserted-by":"crossref","unstructured":"Herrmann C et al (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. 56(2):117\u2013126","DOI":"10.1159\/000201231"},{"issue":"4","key":"3830_CR109","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2337\/diab.43.4.535","volume":"43","author":"C Orskov","year":"1994","unstructured":"Orskov C, Rabenh\u00f8j L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43(4):535\u2013539","journal-title":"Diabetes"},{"issue":"5239","key":"3830_CR110","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.270.5239.1166","volume":"270","author":"N Inagaki","year":"1995","unstructured":"Inagaki N et al (1995) Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270(5239):1166\u20131170","journal-title":"Science"},{"issue":"4","key":"3830_CR111","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0002-9149(73)80051-7","volume":"32","author":"AR Christlieb","year":"1973","unstructured":"Christlieb AR (1973) Diabetes and hypertensive vascular disease. Mechanisms and treatment. Am J Cardiol 32(4):592\u2013606","journal-title":"Mechanisms and treatment. Am J Cardiol"},{"key":"3830_CR112","doi-asserted-by":"crossref","first-page":"F242","DOI":"10.1152\/ajpcell.1995.269.1.C242","volume":"269","author":"DA Linseman","year":"1995","unstructured":"Linseman DA, Lawson JA, Jones DA, Ludens JH (1995) Glyburide attenuates calmodulin antagonist-stimulated renin release from isolated mouse juxtaglomerular cells. Am J Physiol 269:F242-247","journal-title":"Am J Physiol"},{"issue":"1","key":"3830_CR113","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000045248","volume":"81","author":"H Ochi","year":"1999","unstructured":"Ochi H, Ikeda T (1999) Sulfonylureas stimulate renin secretion from the perfused kidney of the rat. Nephron 81(1):67\u201371","journal-title":"Nephron"},{"key":"3830_CR114","doi-asserted-by":"crossref","unstructured":"Deprez P et al (1995) Sulfonylureas and sulfonylcarbamates as new non-tetrazole angiotensin II receptor antagonists. Discovery of a highly potent orally active (imidazolylbiphenylyl) sulfonylurea (HR 720). J Med Chem 38(13):2357\u20132377","DOI":"10.1021\/jm00013a013"},{"key":"3830_CR115","doi-asserted-by":"publisher","first-page":"877797","DOI":"10.3389\/fphar.2022.877797","volume":"13","author":"X Ni","year":"2022","unstructured":"Ni X, Zhang L, Feng X, Tang L (2022) New hypoglycemic drugs: combination drugs and targets discovery. Front Pharmacol 13:877797","journal-title":"Front Pharmacol"},{"key":"3830_CR116","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"3830_CR117","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357","journal-title":"N Engl J Med"},{"key":"3830_CR118","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"key":"3830_CR119","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306","journal-title":"N Engl J Med"},{"key":"3830_CR120","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311\u2013322","journal-title":"N Engl J Med"},{"key":"3830_CR121","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844","journal-title":"N Engl J Med"},{"key":"3830_CR122","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392:1519\u20131529","journal-title":"Lancet"},{"key":"3830_CR123","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121\u2013130","journal-title":"Lancet"},{"issue":"6","key":"3830_CR124","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1055\/s-2008-1042429","volume":"116","author":"J Song","year":"2008","unstructured":"Song J, Liu H, Ressom HW, Tiwari S, Ecelbarger CM (2008) Chronic rosiglitazone therapy normalizes expression of ACE1, SCD1 and other genes in the kidney of obese Zucker rats as determined by microarray analysis. Exp Clin Endocrinol Diabetes 116(6):315\u2013325","journal-title":"Exp Clin Endocrinol Diabetes"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03830-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03830-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03830-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:03:44Z","timestamp":1747209824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03830-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":124,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3830"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03830-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}